This is the first new gout treatment in 40 years. The drug is available in 2 doses, 40 mg and 80 mg. Patients with gout suffer from a building up of uric acid in their system. BD
DEERFIELD, IL and OSAKA, JAPAN, Feb 13, 2009 (MARKET WIRE via COMTEX) ----Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA: 30.7446, -0.8854, -2.8%) has approved ULORIC(R: 30.7446, -0.8854, -2.8%) (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral medication is the first new treatment option in more than 40 years for the more than five million patients who have hyperuricemia associated with gout. ULORIC was discovered by Teijin Pharma Limited (Teijin Pharma) of Tokyo and licensed to Takeda for the U.S. market.
"The approval of ULORIC offers clinicians and their patients who have hyperuricemia associated with gout a new treatment option that helps prevent uric acid production," said Nancy Joseph-Ridge, M.D., president, Takeda Global Research & Development Center, Inc., U.S. "In the years that we've dedicated to studying patients who have gout, I know that many patients go to their doctor during a flare not understanding that gout is a chronic disease that needs to be managed on a long-term, daily basis."